GlycoMimetics to Report Second Quarter Financial Results on August 5, 2021

Rhea-AI Summary

GlycoMimetics, Inc. (Nasdaq: GLYC) will hold a conference call on August 5, 2021, at 8:30 a.m. ET to discuss its second-quarter financial results. Domestic participants can dial (844) 413-7154, while international callers should use (216) 562-0466, entering participant code 9977599. A replay will be available on the company's website and via dial-in for 24 hours post-call. GlycoMimetics, based in Rockville, MD, focuses on glycobiology therapies targeting cancers like acute myeloid leukemia (AML) and has received Breakthrough Therapy Designation for its lead drug, uproleselan.

Positive

• GlycoMimetics is a leader in glycobiology-based therapies for serious diseases.
• Uproleselan has received Breakthrough Therapy Designation in the U.S. and China.
• The company is advancing its pipeline of drug candidates, including a Phase 3 trial for uproleselan in relapsed/refractory AML.

Negative

• None.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Thursday, August 5, 2021, at 8:30 a.m. ET.

The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 9977599. Participants are encouraged to connect 15 minutes in advance of the call to ensure they are able to connect. A webcast replay will be available via the “Investors” tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, with participant code 9977599.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. The Company’s lead drug candidate, uproleselan, has received Breakthrough Therapy Designation in the U.S. and China and is undergoing evaluation across a range of patient populations, including a Phase 3 trial in relapsed/refractory AML. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210729006100/en/

FAQ

When will GlycoMimetics report its second quarter financial results?

GlycoMimetics will report its second quarter financial results on August 5, 2021, at 8:30 a.m. ET.

What is the purpose of the conference call scheduled by GlycoMimetics?

The conference call is to discuss the second quarter financial results for GlycoMimetics.

How can I access the GlycoMimetics conference call?

Participants can dial (844) 413-7154 for domestic calls and (216) 562-0466 for international calls, using participant code 9977599.

What is uproleselan and what is its significance for GlycoMimetics?

Uproleselan is GlycoMimetics' lead drug candidate that has received Breakthrough Therapy Designation and is currently in Phase 3 trials for relapsed/refractory AML.